Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications

With the appointment of Katja Margell as new Head of Corporate Communications Hansa Biopharma seeks to strengthen its communication efforts internally as well as with media and external stakeholders as the Company transitions into a commercial stage biopharmaceutical company.

Lund, Sweden July 16, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that  the Company has appointed Katja Margell as new Head of Corporate Communications. 

Katja brings extensive corporate communications experience as a former partner at Swedish communications agencies Kreab Worldwide and Hallvarsson & Halvarsson where she focused on strategic, corporate and capital markets communication. Prior to this, Katja was Group Communications Manager at Swedish bank SEB and has also held positions within communications and investor relations in companies in the life science sector. Katja holds double Master’s degrees in laws from Vrije Universiteit Brussels and Stockholms University, and she has a background in journalism.

“Katja brings extensive corporate communications experience from leading communications agencies and companies and will be a great addition to the Hansa team as the Company transitions into a commercial stage biopharmaceutical company and expands its proprietary enzyme technology platform beyond transplantation”, says Søren Tulstrup, President & CEO of Hansa Biopharma.

Katja will assume the role as Head of Corporate Communications with immediate effect.

For further information, please contact:
Klaus Sindahl, 
Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell, Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Subscribe

Documents & Links